10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

Authors: Courtney D DiNardo, Abhishek Maiti, Caitlin R Rausch, Naveen Pemmaraju, Kiran Naqvi, Naval G Daver, Tapan M Kadia, Gautam Borthakur, Maro Ohanian, Yesid Alvarado, Ghayas C Issa, Guillermo Montalban-Bravo, Nicholas J Short, Musa Yilmaz, Prithviraj Bose, Elias J Jabbour, Koichi Takahashi, Jan A Burger, Guillermo Garcia-Manero, Nitin Jain, Steven M Kornblau, Philip A Thompson, Zeev Estrov, Lucia Masarova, Koji Sasaki, Srdan Verstovsek, Alessandra Ferrajoli, William G Weirda, Sa A Wang, Sergej Konoplev, Zhining Chen, Sherry A Pierce, Jing Ning, Wei Qiao, Farhad Ravandi, Michael Andreeff, John S Welch, Hagop M Kantarjian, Marina Y Konopleva

Published: 2020-09-06

DOI: 10.1016/s2352-3026(20)30210-6

Source: Full article


Abstract

No abstract found.